Rising
GLP-1 Oral Market Opens with Eli Lilly's Foundayo
Eli Lilly's oral GLP-1 obesity treatment Foundayo received FDA approval on April 1. Cash price set at $149 per month (matching oral Wegovy pricing); Medicare coverage begins summer at $50 per month. Estimated 2030 sales of $14.8 billion.
Primary sources · 1